Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

At the end of the day, weight loss options, like any other health-related decisions, are very personal and must be made on a ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

New obesity management medications, including glucagon-like peptide 1 receptor agonists (GLP-1RAs), have shown high efficacy in clinical trials. Among GLP-1RAs, liraglutide and semaglutide have ...

Feb. 12, 2024 – People with type 2 diabetes taking GLP-1 medicines may experience potentially blinding eye conditions as soon as the day after starting the drugs, and eye doctors are now asking ...

As obesity rates rise, eligibility expands and curiosity about these medications grows ... a triple-hormone-receptor agonist combining GLP-1, GIP and glucagon receptors. Early trial data published ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

"We are pleased to announce last patient/last visit in our Phase 2 obesity study and look forward ... loss beyond those achieved with GLP-1 and GIP drugs," continued Dr. Spana.

This medication also mimics GLP-1, in addition to ... polypeptide (or GIP), which plays a role in fat metabolism. Beyond treating type 2 diabetes and obesity, GLP-1 drugs are showing surprising ...

UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...